Optimizing denileukin diftitox (Ontak) therapy
- PMID: 18684057
- DOI: 10.2217/14796694.4.4.457
Optimizing denileukin diftitox (Ontak) therapy
Abstract
Denileukin diftitox (Ontak) is a novel recombinant fusion protein consisting of peptide sequences for the enzymatically active and membrane translocation domain of diphtheria toxin linked to human IL-2. Denileukin diftitox specifically binds to IL-2 receptors on the cell membrane, is internalized via receptor-mediated endocytosis and inhibits protein synthesis by ADP ribosylation of elongation factor 2, resulting in cell death. This article focuses on the clinical trial that led to the US FDA approval of the drug for cutaneous T-cell lymphoma in 1999, and other investigational studies for hematologic malignancies, recurrent and refractory chronic lymphocytic leukemia, non-Hodgkin B-cell lymphoma, graft-versus-host disease and autoimmune disease, demonstrating the activity and adverse effects of the drug.
Similar articles
-
Clinical experience with denileukin diftitox (ONTAK).Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. doi: 10.1053/j.seminoncol.2005.12.017. Semin Oncol. 2006. PMID: 16516670 Review.
-
Denileukin diftitox: a concise clinical review.Expert Rev Anticancer Ther. 2005 Feb;5(1):33-8. doi: 10.1586/14737140.5.1.33. Expert Rev Anticancer Ther. 2005. PMID: 15757436 Review.
-
Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. doi: 10.1586/14737140.7.1.11. Expert Rev Anticancer Ther. 2007. PMID: 17187516 Review.
-
Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.Am J Hematol. 2008 Jul;83(7):593-5. doi: 10.1002/ajh.21180. Am J Hematol. 2008. PMID: 18335564
-
Denileukin diftitox.Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. doi: 10.2165/00128071-200001010-00008. Am J Clin Dermatol. 2000. PMID: 11702307 Review.
Cited by
-
Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Expert Opin Biol Ther. 2013 May;13(5):657-71. doi: 10.1517/14712598.2013.761969. Epub 2013 Jan 7. Expert Opin Biol Ther. 2013. PMID: 23293858 Free PMC article. Review.
-
Transforming Healthcare with Nanomedicine: A SWOT Analysis of Drug Delivery Innovation.Drug Des Devel Ther. 2024 Aug 5;18:3499-3521. doi: 10.2147/DDDT.S470210. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39132625 Free PMC article. Review.
-
Toxic proteins in plants.Phytochemistry. 2015 Sep;117:51-64. doi: 10.1016/j.phytochem.2015.05.020. Epub 2015 Jun 7. Phytochemistry. 2015. PMID: 26057229 Free PMC article. Review.
-
Application of lipid nanovesicle drug delivery system in cancer immunotherapy.J Nanobiotechnology. 2022 May 6;20(1):214. doi: 10.1186/s12951-022-01429-2. J Nanobiotechnology. 2022. PMID: 35524277 Free PMC article. Review.
-
pH-triggered conformational switching along the membrane insertion pathway of the diphtheria toxin T-domain.Toxins (Basel). 2013 Aug 6;5(8):1362-80. doi: 10.3390/toxins5081362. Toxins (Basel). 2013. PMID: 23925141 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
